|
Basic Characteristics of Mutations
|
|
Mutation Site
|
A82V |
|
Mutation Site Sentence
|
Fixed changes in amino acid sequence, such as A82V in the EBOV glycoprotein (GP) that occurred early in the 2013-16 epidemic, are suspected to confer a selective advantage to the virus. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
GP |
|
Standardized Encoding Gene
|
GP
|
|
Genotype/Subtype
|
Makona;Mayinga |
|
Viral Reference
|
KJ660346
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
NPC1
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
28238624
|
|
Title
|
Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013-16 Epidemic
|
|
Author
|
Wang MK,Lim SY,Lee SM,Cunningham JM
|
|
Journal
|
Cell host & microbe
|
|
Journal Info
|
2017 Mar 8;21(3):367-375
|
|
Abstract
|
Ebola virus (EBOV) infection is characterized by sporadic outbreaks caused by zoonotic transmission. Fixed changes in amino acid sequence, such as A82V in the EBOV glycoprotein (GP) that occurred early in the 2013-16 epidemic, are suspected to confer a selective advantage to the virus. We used biochemical assays of GP function to show that A82V, as well as a polymorphism in residue 544 identified in other outbreaks, enhances infection by decreasing the threshold for activation of membrane fusion activity triggered by the host factors cathepsin B and Niemann-Pick C1. Importantly, the increase in infectivity comes with the cost of decreased virus stability. Thus, emergence of a virus GP with altered properties that can affect transmission and virulence may have contributed to the severity and scope of the 2013-16 EBOV epidemic.
|
|
Sequence Data
|
-
|